title: Serious Pulmonary Toxicity Secondary to Novel Hepatitis C Antiviral Therapy in a Liver Transplant Recipient.
abstract: Historically, the treatment of hepatitis C virus infection has been difficult, but therapeutic options have improved markedly recently because of the development of novel antiviral therapies. These therapies have been well tolerated. We describe a patient who was receiving such therapy and had development of temporally related and histologically confirmed severe pulmonary toxicity. Pulmonary toxicity should be considered a potential serious complication of novel antiviral therapy for hepatitis C virus infection.
authors.affiliation: Department of Critical Care Medicine, Mayo Clinic, Phoenix, AZ. Electronic address: helmers.richard@mayo.edu.
authors.forename: Richard A
authors.initials: RA
authors.lastname: Helmers
authors.affiliation: Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, AZ.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Byrne
authors.affiliation: Division of Pulmonary Medicine, Mayo Clinic, Scottsdale, AZ.
authors.forename: Lewis J
authors.initials: LJ
authors.lastname: Wesselius
authors.affiliation: Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ.
authors.forename: Kevin O
authors.initials: KO
authors.lastname: Leslie
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D011658:Pulmonary Fibrosis / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D012307:Risk Factors; D000069616:Simeprevir / Q000008:administration & dosage / Q000009:adverse effects; D000069474:Sofosbuvir / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000069616:Simeprevir; D000069474:Sofosbuvir